Cargando…

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report

The main method of fighting against colon cancer is targeted treatment. BRAF inhibitors, which are accepted as standard treatment for V600E mutant malign melanomas, are the newest approach for targeted treatment of V600E mutant colorectal cancers. In this case report, we share our experience about t...

Descripción completa

Detalles Bibliográficos
Autores principales: Peker, Yasar Subutay, Can, Mehmet Fatih, Ozerhan, Ismail Hakki, Yagci, Gokhan, Zeybek, Nazif, Kavakli, Kutan, Gurkok, Sedat, Gozubuyuk, Alper, Genc, Onur, Erdem, Gokhan, Ozet, Ahmet, Gerek, Mustafa, Peker, Yusuf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5925159/
https://www.ncbi.nlm.nih.gov/pubmed/29850361
http://dx.doi.org/10.1155/2018/8782328
_version_ 1783318660011524096
author Peker, Yasar Subutay
Can, Mehmet Fatih
Ozerhan, Ismail Hakki
Yagci, Gokhan
Zeybek, Nazif
Kavakli, Kutan
Gurkok, Sedat
Gozubuyuk, Alper
Genc, Onur
Erdem, Gokhan
Ozet, Ahmet
Gerek, Mustafa
Peker, Yusuf
author_facet Peker, Yasar Subutay
Can, Mehmet Fatih
Ozerhan, Ismail Hakki
Yagci, Gokhan
Zeybek, Nazif
Kavakli, Kutan
Gurkok, Sedat
Gozubuyuk, Alper
Genc, Onur
Erdem, Gokhan
Ozet, Ahmet
Gerek, Mustafa
Peker, Yusuf
author_sort Peker, Yasar Subutay
collection PubMed
description The main method of fighting against colon cancer is targeted treatment. BRAF inhibitors, which are accepted as standard treatment for V600E mutant malign melanomas, are the newest approach for targeted treatment of V600E mutant colorectal cancers. In this case report, we share our experience about the use of BRAF inhibitor vemurafenib on a V600E mutant metastatic right colon adenocarcinoma patient. A 59-year-old male with only lung multiple metastatic V600E mutant right colon cancer presented to our clinic. The patient was evaluated and FOLFOX + bevacizumab treatment was initiated, which was then continued with vemurafenib. A remarkable response was achieved with vemurafenib treatment in which the drug resistance occurred approximately in the sixth month. Even though the patient benefited majorly from vemurafenib, he died on the 20th month of the diagnosis. The expected overall survival for metastatic V600E mutant colon adenocarcinoma patients is 4.7 months. BRAF inhibitors provide new treatment alternatives for V600E mutant colorectal cancers, with prolonged overall survival. BRAF inhibitors in combination with MEK inhibitors are reported as feasible treatment to overcome BRAF inhibitor drug resistance on which phase studies are still in progress. To conclude, BRAF inhibitors alone or in combination with other drugs provide a chance for curing BRAF V600E mutant colorectal cancer patients.
format Online
Article
Text
id pubmed-5925159
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-59251592018-05-30 BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report Peker, Yasar Subutay Can, Mehmet Fatih Ozerhan, Ismail Hakki Yagci, Gokhan Zeybek, Nazif Kavakli, Kutan Gurkok, Sedat Gozubuyuk, Alper Genc, Onur Erdem, Gokhan Ozet, Ahmet Gerek, Mustafa Peker, Yusuf Case Rep Surg Case Report The main method of fighting against colon cancer is targeted treatment. BRAF inhibitors, which are accepted as standard treatment for V600E mutant malign melanomas, are the newest approach for targeted treatment of V600E mutant colorectal cancers. In this case report, we share our experience about the use of BRAF inhibitor vemurafenib on a V600E mutant metastatic right colon adenocarcinoma patient. A 59-year-old male with only lung multiple metastatic V600E mutant right colon cancer presented to our clinic. The patient was evaluated and FOLFOX + bevacizumab treatment was initiated, which was then continued with vemurafenib. A remarkable response was achieved with vemurafenib treatment in which the drug resistance occurred approximately in the sixth month. Even though the patient benefited majorly from vemurafenib, he died on the 20th month of the diagnosis. The expected overall survival for metastatic V600E mutant colon adenocarcinoma patients is 4.7 months. BRAF inhibitors provide new treatment alternatives for V600E mutant colorectal cancers, with prolonged overall survival. BRAF inhibitors in combination with MEK inhibitors are reported as feasible treatment to overcome BRAF inhibitor drug resistance on which phase studies are still in progress. To conclude, BRAF inhibitors alone or in combination with other drugs provide a chance for curing BRAF V600E mutant colorectal cancer patients. Hindawi 2018-04-15 /pmc/articles/PMC5925159/ /pubmed/29850361 http://dx.doi.org/10.1155/2018/8782328 Text en Copyright © 2018 Yasar Subutay Peker et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Peker, Yasar Subutay
Can, Mehmet Fatih
Ozerhan, Ismail Hakki
Yagci, Gokhan
Zeybek, Nazif
Kavakli, Kutan
Gurkok, Sedat
Gozubuyuk, Alper
Genc, Onur
Erdem, Gokhan
Ozet, Ahmet
Gerek, Mustafa
Peker, Yusuf
BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
title BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
title_full BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
title_fullStr BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
title_full_unstemmed BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
title_short BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
title_sort braf inhibitors for braf v600e mutant colorectal cancers: literature survey and case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5925159/
https://www.ncbi.nlm.nih.gov/pubmed/29850361
http://dx.doi.org/10.1155/2018/8782328
work_keys_str_mv AT pekeryasarsubutay brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport
AT canmehmetfatih brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport
AT ozerhanismailhakki brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport
AT yagcigokhan brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport
AT zeybeknazif brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport
AT kavaklikutan brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport
AT gurkoksedat brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport
AT gozubuyukalper brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport
AT genconur brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport
AT erdemgokhan brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport
AT ozetahmet brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport
AT gerekmustafa brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport
AT pekeryusuf brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport